Inhaled Corticosteroids and Risk of Lung Cancer among Patients with Chronic Obstructive Pulmonary Disease

Parimon, Tanyalak; Chien, Jason W.; Bryson, Chris L.; McDonell, Mary B.; Udris, Edmunds M.; Au, David H.

doi:10.1164/rccm.200608-1125oc

Cited by 182 publications

(160 citation statements)

References 83 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…Two retrospective cohort studies suggest that inhaled corticosteroids may be protective against lung cancer [59,60]. A dose-response relationship has been observed between exposure to inhaled corticosteroids and the reduction in the risk of lung cancer.…”

Section: Preventing Lung Cancer In Copdmentioning

confidence: 99%

Comorbidities of COPD

Cavaillès¹,

Brinchault-Rabin²,

Dixmier³

et al. 2013

European Respiratory Review

410

285

View full text Add to dashboard Cite

By 2020, chronic obstructive pulmonary disease (COPD) will be the third cause of mortality. Extrapulmonary comorbidities influence the prognosis of patients with COPD. Tobacco smoking is a common risk factor for many comorbidities, including coronary heart disease, heart failure and lung cancer. Comorbidities such as pulmonary artery disease and malnutrition are directly caused by COPD, whereas others, such as systemic venous thromboembolism, anxiety, depression, osteoporosis, obesity, metabolic syndrome, diabetes, sleep disturbance and anaemia, have no evident physiopathological relationship with COPD. The common ground between most of these extrapulmonary manifestations is chronic systemic inflammation.All of these diseases potentiate the morbidity of COPD, leading to increased hospitalisations and healthcare costs. They can frequently cause death, independently of respiratory failure. Comorbidities make the management of COPD difficult and need to be evaluated and treated adequately. @ERSpublications Extrapulmonary comorbidities are common in COPD and influence prognosis; we propose an exhaustive comorbidities review

show abstract

Section: Preventing Lung Cancer In Copdmentioning

confidence: 99%

Comorbidities of COPD

Cavaillès¹,

Brinchault-Rabin²,

Dixmier³

et al. 2013

European Respiratory Review

410

285

View full text Add to dashboard Cite

show abstract

“…An observational epidemiological study performed on data from patients diagnosed with chronic obstructive pulmonary disease (COPD) found that inhaled corticosteroid use resulted in a lower incidence of lung cancer (Parimon et al 2007). COPD is a risk factor for lung cancer because of its association with smoking and inflammation.…”

Section: The Effects Of Gc Monotherapy On Nsclcmentioning

confidence: 99%

Glucocorticoid receptors in lung cancer: new perspectives

Taylor

Ray

Sommer

2016

Journal of Endocrinology

View full text Add to dashboard Cite

Proper expression of the glucocorticoid receptor (GR) plays an essential role in the development of the lung. GR expression and signalling in the lung is manipulated by administration of synthetic glucocorticoids (Gcs) for the treatment of neonatal, childhood and adult lung diseases. In lung cancers, Gcs are also commonly used as co-treatment during chemotherapy. This review summarises the effect of Gc monotherapy and co-therapy on lung cancers in vitro, in mouse models of lung cancer, in xenograft, ex vivo and in vivo. The disparity between the effects of pre-clinical and in vivo Gc therapy is commented on in light of the recent discovery of GR as a novel tumour suppressor gene.

show abstract

“…Regular use of an inhaled glucocorticoid may reduce the risk of lung cancer among former smokers with COPD [81,82]. However, long-term inhalation of high-dose glucocorticoids did not induce any regression of bronchial dysplasia or secondary markers of carcinogenesis in smokers [83] and did not decrease the risk of lung cancer [84].…”

Section: Lung Cancer Prevention In Copd Patientsmentioning

confidence: 99%

Early detection of COPD is important for lung cancer surveillance

Sekine¹,

Katsura²,

Koh³

et al. 2011

Eur Respir J

123

101

View full text Add to dashboard Cite

It is well known that chronic obstructive pulmonary disease (COPD) is a significant risk factor for lung cancer. Approximately 1% of COPD patients develop lung cancer every year, which may be associated with genetic susceptibility to cigarette smoke. Chronic inflammation caused by toxic gases can induce COPD and lung cancer. Inflammatory mediators may promote the growth of bronchioalveolar stem cells, and activation of nuclear factor-kB and signal transducer and activator of transcription 3 play crucial roles in the development of lung cancer from COPD.Low-dose computed tomography (LDCT) is an effective procedure for the early detection of lung cancer in high-risk patients. However, determining which patients should be screened for lung cancer in a primary care setting is difficult. In this article, we review the epidemiology and aetiology of lung cancer associated with COPD, verify the efficacy of lung cancer screening by LDCT, and discuss the importance of early detection of COPD for lung cancer surveillance.We propose that, for the prevention of both diseases, COPD screening in smokers should be initiated as early as possible, so they can stop smoking and so that candidates for an efficient lung cancer screening programme can be identified.

show abstract

Inhaled Corticosteroids and Risk of Lung Cancer among Patients with Chronic Obstructive Pulmonary Disease

Cited by 182 publications

References 83 publications

Comorbidities of COPD

Comorbidities of COPD

Glucocorticoid receptors in lung cancer: new perspectives

Early detection of COPD is important for lung cancer surveillance

Contact Info

Product

Resources

About